Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.97), $0.12 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $456.4 million versus the consensus estimate of $430.55 million.

GUIDANCE:

Exact Sciences sees 2021 revenue of $1.72-1.74 billion, versus the consensus of $1.73 billion.

• The company anticipates revenue of $1,722-$1,737 million during 2021, including Screening revenue of $1,050-$1,055 million, Precision Oncology revenue of $547-$552 million, and COVID-19 testing revenue of $125-$130 million.
• Updated revenue guidance has been narrowed toward the high end of our previously expected range of $1,705-$1,745 million, which included Screening revenue of $1,100-$1,125 million, Precision Oncology revenue of $530-$540 million, and COVID-19 testing revenue of $75-$80 million.
• Screening revenue expectations are lower due to the rapid rise in Delta variant cases starting in late July, causing in-person sales calls to significantly decrease in August and September.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.